NCT06643156View on ClinicalTrials.gov

Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

January 18, 2025

Study Completion Date

January 18, 2025

Conditions
Influenza
Interventions
DRUG

GP681 10mg/20mg/40mg

0.5/1/2×20mg power for oral suspension taken orally

Trial Locations (1)

315042

Ningbo Women and Children's hospital, Ningbo

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY